Structure—Function Relationships in G Protein-Coupled Receptors: Ligand Binding and Receptor Activation

Contemporary Clinical Neuroscience

Volumn , Issue , 2005, Pages 3-31

  Massotte, Dominique ^a   Kieffer, Brigitte L ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Biogenic Amine Receptor; Extracellular Loop; Intracellular Loop; Opioid Receptor; Ternary Complex Model

Indexed keywords

EID: 77956550942     PISSN: 2627535X     EISSN: 26275341     Source Type: Book Series    
DOI: 10.1007/978-1-59259-919-6_1     Document Type: Chapter

References (120)

1. Consortium IHGS. Initial sequensing and analysis of the human genome. Nature 2001;409:860–922.
2. Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003;63:1256–1272.
3. Flower DR. Modelling G-protein-coupled receptors for drug design. Biochim Biophys Acta 1999;1422:207–234.
4. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmakol 2002;366:381–416.
5. Klabunde T, Hessler G. Drug design strategies for targeting G-proteincoupled receptors. Chem Bio Chem2002;3:928–944.
6. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90–113.
7. Lu Z-L, Saldanha JW, Hulme EC. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 2002;23:140–146.
8. Tsao P, Cao T, von Zastrow M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol Sci 2001;22:91–96.
9. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003;63:9–18.
10. Hur E-M, Kim K-T. G protein-coupled receptors signalling and cross-talk. achieving rapidity and specificity. Cell Signal 2002;14:397–405.
11. Ishii M, Kurachi Y. Physiological actions of regulators of G-protein signaling (RGS) proteins. Life Sci 2003;74:163–171.
12. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739–745.
13. Massotte D. G protein-coupled receptor overexpression with the baculovirusinsect cell system: a tool for structural and functional studies. Biochim Biophys Acta 2003;1610:77–89.
14. Kunishima N, Shimada Y, Tsuji Y, et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000;407:971–977.
15. Malbon CC, Wang H, Moon RT. Wnt signaling and heterotrimeric G-proteins: strange bedfellows or a classic romance? Biochem Biophys Res Commun 2001;287:589–593.
16. Vaidehi N, Floriano WB, Trabanino R, et al. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA 2002;99: 12,622–12,627.
17. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure–function analysis of rhodopsin-like receptors. Mol Pharmacol 2001;60:1–19.
18. Strader CD, Fong TM, Graziano MP, Tota MR. The family of G-proteincoupled receptors. FASEB J 1995;9:745–754.
19. Surratt CK, Johnson PS, Moriwaki A, et al. mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 1994;269:20,548–20,553.
20. Befort K, Tabbara L, Bausch S, Chavkin C, Evans C, Kieffer BL. The conserved aspartate residue in the third putative transmembrane domain of the δ opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol 1996;49:216–223.
21. Befort K, Tabbara L, Kling D, Maigret B, Kieffer BL. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J Biol Chem 1996;271:10,161–10,168.
22. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor–ligand interactions. J Biol Chem 1998;273:17,299–17,302.
23. Marshall GR. Peptide interactions with G-protein coupled receptors. Biopolymers 2001;60:246–277.
24. Zhao MM, Hwa J, Perez DM. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 1996;50:1118–1126.
25. Wang WW, Shahrestanifar M, Jin J, Howells RD. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc Natl Acad Sci USA 1995;92:12,436–12,440.
26. Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR. Human kappa opiate receptor second extracellular loop elevates dynorphin’s affinity for human mu/kappa chimeras. J Biol Chem 1994;269:25,966–25,969.
27. Varga EV, Li X, Stropova D, et al. The third extracellular loop of the human δ-opioid receptor determines the selectivity of the δ-opioid agonists. Mol Pharmacol 1997;50:1619–1624.
28. Law PY, Wong YH, Loh HH. Mutational analysis of the structure and function of opioid receptors. Biopolymers 1999;51:440–455.
29. Pepin MC, Yue SY, Roberts E, Wahlestedt C, Walker P. Novel “restoration of function” mutagenesis strategy to identify amino acids of the delta-opioid receptor involved in ligand binding. J Biol Chem 1997;272:9260–9267.
30. Xue J-C, Chen C, Zhu J, et al. The third extracellular loop of the μ opioid receptor is important for agonist selectivity. J Biol Chem 1995;270:12,977– 12,979.
31. Shi L, Javitch JA. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 2004;101:440–445.
32. Schwartz TW, Rosenkilde MM. Is there a ‘lock’ for all agonist ‘keys’ in 7TM receptors? Trends Pharmacol Sci 1996;17:213–216.
33. Zhang P, Johnson PS, Zoellner C, et al. Mutation of human μ opioid receptor extracellular “disulfide cysteine” residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Mol Brain Res 1999;72:195–204.
34. Baneres J-L, Martin A, Hullot P, Girard J-P, Rossi J-C, Parello J. Structurebased analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1. J Mol Biol 2003;329:801–814.
35. Savarese TM, Wang CD, Fraser CM. Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. J Biol Chem 1992;267:11,439–11,448.
36. D’Angelo DD, Eubank JJ, Davis MG, Dorn GW 2nd. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor–effector coupling J Biol Chem 1996;271:6233–6240.
37. Perlman JH, Wang W, Nussenzveig DR, Gershengorn MC. A disulfide bond between conserved extracellular cysteines in the thyrotropin-releasing hormone receptor is critical for binding. J Biol Chem 1995;270:24,682–24,685.
38. Cook JV, Eidne KA. An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation Endocrinology 1997;138:2800–2806.
39. Yamano Y, Ohyama K, Chaki S, Guo DF, Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem Biophys Res Commun 1992;187:1426–1431.
40. Noda K, Saad Y, Graham RM, Karnik SS. The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and nonconserved extracellular loop cysteines. J Biol Chem 1994;269:6743–6752.
41. Elling CE, Nielsen SM, Schwartz TW. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Nature 1995;374:74–77.
42. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980;255:7108–7117.
43. Costa T, Herz A. Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989;86:7321–7325.
44. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993;268:4625–4636.
45. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. I. model description. J Theor Biol 1996;178:151–167.
46. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 1997;272:22,330–22,339.
47. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002;54:323–374.
48. Zuscik MJ, Porter JE, Gaivin R, Perez DM. Identification of a conserved switch residue responsible for selective constitutive activation of the beta2adrenergic receptor. J Biol Chem 1998;273:3401–3407.
49. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 2003;24:346–354.
50. 1B-adrenergic receptor by all amino acid substitution at a single site. J Biol Chem 1992;267:1430–1433.
51. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metabol 2002;13:336–343.
52. Gether U, Asmar F, Meinild AK, Rasmussen SG. Structural basis for activation of G-protein-coupled receptors. Pharmacol Toxicol 2002;91:304–312.
53. Gether U, Ballesteros JA, Seifert R, Sansers-Bush E, Weinstein H, Kobilka BK. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 1997;272:2587–2590.
54. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996;383:347–350.
55. Sheikh SP, Vilardarga JP, Baranski TJ, et al. Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J Biol Chem 1999;274:17,033–17,041.
56. Javitch JA, Fu D, Liapakis G, Chen J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 1997;272:18,546–18,549.
57. Spalding TA, Burstein ES, Henderson SC, Ducote KR, Brann MR. Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 1998;273:21,563–21,568.
58. Décaillot FM, Befort K, Filliol D, Yue SY, Walker P, Kieffer BL. Opioid receptor random mutagenesis reveals how a G protein-coupled receptor turns on. Nat Struct Biol 2003;10:629–636.
59. Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, Clauser E. Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci USA 2000;97:7615–7620.
60. Baranski TJ, Herzmark P, Lichtarge O, et al. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J Biol Chem 1999;274:15,757–15,765.
61. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002;277:11,441–11,449.
62. Alewijnse AE, Timmerman H, Jacobs EH, et al. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol Pharmacol 2000;57:890–898.
63. Sheer A, Cotecchia S. Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J Recept Signal Transduct Res 1997;17:57–73.
64. Ballesteros JA, Jensen AD, Liapakis G, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001;276:29,171–29,177.
65. Burstein ES, Spalding TA, Brann MR. The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 1998;273:24,322–24,327.
66. Yamashita T, Terakita A, Shichida Y. Distinct roles of the second and third cytoplasmic loops of bovine rhodopsin in G protein activation. J Biol Chem 2000;275:34,272–34,279.
67. Demene H, Granier S, Muller D, et al. Active peptidic mimics of the second intracellular loop of the V(1A) vasopressin receptor are structurally related to the second intracellular rhodopsin loop: a combined 1H NMR and biochemical study. Biochemistry 2003;42:8204–8213.
68. Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR. NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry 2002;41:3596–3604.
69. Chung DA, Wade SM, Fowler CB, et al. Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors. Biochem Biophys Res Commun 2002;293:1233–1241.
70. Huang P, Li J, Chen C, Visiers I, Weinstein H, Liu-Chen LY. Functional role of a conserved motif in TM6 of the rat μ opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 2001;40:13,501–13,509.
71. Huang P, Visiers I, Weinstein H, Liu-Chen L-Y. The local environment at the cytoplasmic end of TM6 of the m opioid receptor differs from those of rhodopsin and monoamine receptors: introduction of an ionic lock between the cytoplasmic ends of helices 3 and 6 by a L6.30(275)E mutation inactivates the μ opioid receptor and reduces the constitutive activity of its T6.34(279)K mutant. Biochemistry 2002;41:11,972–11,980.
72. Javitch JA, Shi L, Simpson MM, et al. The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 2000;39:12,190– 12,199.
73. Chen S, Lin F, Xu M, Graham RM. Phe(303) in TMVI of the alpha(1B) adrenergic receptor is a key residue coupling TM helical movements to Gprotein activation. Biochemistry 2002;41:588–596.
74. Jagerschmidt A, Guillaume N, Roques BP, Noble F. Binding sites and transduction process of the cholecystokinin B receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Mol Pharmacol 1998;53:878–885.
75. Lu ZL, Hulme EC. A network of conserved intramolecular contacts defines the off-state of the transmembrane switch mechanism in a seven-transmembrane receptor. J Biol Chem 2000;275:5682–5686.
76. Han M, Smith SO, Sakmar TP. Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 1998;37:8253–8261.
77. Laue L, Chan WY, Hsueh AJ, et al. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci USA 1995;92:1906–1910.
78. Vlaeminck-Guillem V, Ho SC, Rodien P, Vassart G, Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 2002;16:736–746.
79. Jin H, Xie Z, George SR, O’Dowd BF. Palmitoylation occurs at cysteine 347 and cysteine 351 of the dopamine D1 receptor. Eur J Pharmacol 1999;386:305–312
80. Ponimaskin EG, Heine M, Joubert L, et al. The 5-hydroxytryptamine(4a) receptor is palmitoylated at two different sites and acylation is critically involved n regulation of receptor constitutive activity. J Biol Chem 2002;277:2534–2546.
81. 1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration. J Biol Chem 2001;276:38,139–38,146.
82. Morrison DF, O’Brien PJ, Pepperbeg DR. Depalmitoylation with hydroxylamine alters the functional properties of rhodopsin. J Biol Chem 1991;266:20,118–20,123.
83. Krishna AG, Menon ST, Terry TJ, Sakmar TP. Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch. Biochemistry 2002;41:8298–8309.
84. Ponimaskin EG, Schmidt MF, Heine M, Bickmeyer U, Richter DW. 5-Hydroxytryptamine 4(a) receptor expressed in Sf9 cells is palmitoylated in an agonist-dependent manner. Biochem J 2001;353:627–634.
85. Brillet K, Kieffer BL, Massotte D. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening. BMC Pharmacol 2003;3:14.
86. Doi T, Sugimoto H, Arimoto I, Hiroaki Y, Fujiyoshi Y. Interactions of endothelin receptor subtypes A and B with Gi, Go, and Gq in reconstituted phospholipid vesicles. Biochemistry 1999;38:3090–3099.
87. Horstmeyer A, Cramer H, Sauer T, Mueller-Esterl W, Schroeder C. Palmitoylation of endothelin A. Differential modulation of signal transduction activity by post-translational modification. J Biol Chem 1996;271:20,811–20,819.
88. B. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J Biol Chem 1997;272:21,589–21,596.
89. Mouillac B, Caron M, Dennis M, Bouvier M. Agonist-modulated palmitoylation of β2-adrenergic receptor in Sf9 cells. J Biochem (Tokyo) 1992;267:21,733–21,737.
90. s. J Biol Chem 1999;274:31,014–31,019.
91. Kennedy M, Limbird L. Mutations of the alpha 2A-adrenergic receptor that eliminate detectable palmitoylation do not perturb receptor–G-protein coupling. J Biol Chem 1993;268:8003–8011.
92. Hayashi M, Haga T. Palmitoylation of muscarinic acetylcholine receptor m2 subtypes: reduction in their ability to activate G proteins by mutation of a putative palmitoylation site, cysteine 457, in the carboxy-terminal tail. Arch Biochem Biophys 1997;340:376–382.
93. 2-adrenergic receptor by the cAMP-dependent protein kinase. J Biol Chem 1996;271:21,491–21,497.
94. Palmer TM, Stiles GL. Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A(3) adenosine receptor. Mol Pharmacol 2000;57:539–545.
95. Soskic V, Nyakatura E, Roos M, Muller-Esterl W, Godovac-Zimmermann J. Correlations in palmitoylation and multiple phosphorylation of rat bradykinin B2 receptor in Chinese hamster ovary cells. J Biol Chem 1999;274:8539–8545.
96. Chen C, Shahabi V, Xu W, Liu-Chen L-Y. Palmitoylation of the rat μ opioid receptor. FEBS Lett 1998;441:148–152.
97. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003;99:25–44.
98. Schwindinger WF, Robishaw JD. Heterotrimeric G-protein betagammadimers in growth and differentiation. Oncogene 2001;20:1653–1660.
99. Wong SK. G protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals 2003;12:1–12.
100. s. J Neurochem 1999;72:2032–2038.
101. Slessareva JE, Ma H, Depree KM, et al. Closely related G-protein-coupled receptors use multiple and distinct domains on G-protein alpha-subunits for selective coupling. J Biol Chem 2003;278:50,530–50,536.
102. Seifert R, Gether U, Wenzel-Seifert K, Kobilka BK. Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 1999;56:348–358.
103. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA 2001;98:5997–6002.
104. i2 α fused to the human mu opioid receptor differently. J Neurochem 2002;81:1372–1382.
105. Moon H-E, Cavalli A, Bahia DS, Hoffmann M, Massotte D, Milligan G. The human δ opioid receptor activates Gi1α more efficiently than Go1α. J Neurochem 2001;76:1–10.
106. Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, Hruby VJ. Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem 2003;278:48,890–48,897.
107. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 2004;279:686–691.
108. Palanche T, Ilien B, Zoffmann S, et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 2001;276:34,853–34,861.
109. Zamah AM, Delahunty M, Luttrell LM, Lefkowitz RJ. Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system. J Biol Chem 2002;277:31,249–31,256.
110. i/o-proteins. Mol Pharmacol 2002;61:85–96.
111. Namba T, Sugimoto Y, Negishi M, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993;365:166–170.
112. Negishi M, Namba T, Sugimoto Y, et al. Opposite coupling of prostaglandin E receptor EP3C with Gs and G(o). Stimulation of Gs and inhibition of G(o). J Biol Chem 1993;268:26,067–26,070.
113. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 2001;134:386–392.
114. Charles AC, Mostovskaya N, Asass K, Evans CJ, Dankovich ML, Hales TG. Coexpression of delta-opioid receptors with mu receptors in GH3 cells changes the functional response to mu agonists from inhibitory to excitatory. Mol Pharmacol 2003;63:89–95.
115. George SR, Fan T, Xie Z, et al. Oligomerization of mu-and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000;275:26,128–26,135.
116. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000;407:94–98.
117. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et al. Chemokine receptor homo-or heterodimerization activates distinct signaling pathways. EMBO J 2001;20:2497–2507.
118. Hall RA, Lefkowitz RJ. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res 2002;91:672–680.
119. Bockaert J, Marin P, Dumuis A, Fagni L. The ‘magic tail’ of G proteincoupled receptors: an anchorage for functional protein networks. FEBS Lett 2003;546:65–72.
120. Wang D, Sadee W, Quillan JM. Calmodulin binding to G protein-coupling domain of opioid receptors. J Biol Chem 1999;274:22,081–22,088.